X

Drug Profile

Tecadenoson

Alternative Names: CVT 510

Latest Information Update: 16 Mar 2010

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CV Therapeutics
Developer CV Therapeutics; Gilead Sciences
Class Antiarrhythmics; Furans; Purine nucleosides; Ribonucleosides; Small molecules
Mechanism of Action Adenosine A1 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Atrial fibrillation; Paroxysmal supraventricular tachycardia

Most Recent Events

16 May 2009 Discontinued - Phase-III for Paroxysmal supraventricular tachycardia in USA (IV)
17 Apr 2009 CV Therapeutics has been acquired and merged into Gilead Sciences
13 Nov 2007 Preclinical data added to the Arrhythmias pharmacodynamics section

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com